A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This is a placebo-controlled, randomized, multicenter Phase III study that will evaluate the
safety and efficacy of bevacizumab, administered in combination with carboplatin with
gemcitabine, in women with platinum-sensitive recurrent epithelial ovarian, primary
peritoneal, or fallopian tube carcinoma.